Petros Pharmaceuticals Inc

NASDAQ:PTPIUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.

Contact Information

Headquarters

1185 Avenue Of The Americas 3Rd Floor, Suite 570NEW YORK, NY, United States 10036

Phone

973-242-0005

Fax

302-655-5049

Executives

President, Chief Commercial Officer

Fady Boctor

Independent Vice Chairman of the Board

Joshua Silverman

Chief Accounting Officer, Vice President - Finance

Mitchell Arnold

Independent Director

Bruce Bernstein

Independent Director

Wayne Walker